Wunderman names global ops head

Share this article:
Wunderman named Becky Chidester to head up its global healthcare operations.

Chidester, who was previously president of Wunderman New York, will lead the WPP direct shop's worldwide health offering as president, Wunderman World Health, a new position. She will be based in Washington, DC, reporting to chairman and CEO Daniel Morel.

She will be supported by a core strategic team of health care experts from New York and Singapore as well as Wunderman network partners KnowledgeBase Marketing and RTCRM, the shop said.

“My first order of business is to unite all the diverse healthcare capabilities within Wunderman,” said Chidester. “I'm looking at healthcare from a fairly wide angle.”

The elevation of Chidester, who comes to the job with a strong public policy background, is indicative of the growing importance of government relations and managed markets to the business.

Chidester started her career as a staffer for Indiana Senator Birch Bayh, before moving on to work for a chemical manufacturer's trade association and then heading Reese Communications. After Reese was acquired by WPP, it was folded into RTC Relationship Marketing, which in turn fell under the Wunderman umbrella.

Wunderman has created similar practice leader positions for its automotive and Microsoft businesses. Previously, leadership fell to individual offices, said a spokesman.

Headquartered in New York, the network's health offering includes data, direct and digital marketing for pharmaceuticals, health insurance, services and devices, OTC drugs and nutritional supplements, eye care and wellness products.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.